Tumors of the Central Nervous System, Volume 5 - Astrocytomas, Hemangioblastomas, and Gangliogliomas (Cartonné)

Edition en anglais

  • Springer

  • Paru le : 01/10/2011
Note moyenne : |
Ce produit n'a pas encore été évalué. Soyez le premier !
Donnez votre avis !
pThe most recent developments in diagnostic and therapeutic aspects of Gliomas (glioblastoma) in the brain are presented. �The importance of personalized... > Lire la suite
149,75 €
Neuf - Expédié sous 9 à 14 jours
  • ou
    Livré chez vous
    entre le 6 décembre et le 9 décembre
ou
Votre note
pThe most recent developments in diagnostic and therapeutic aspects of Gliomas (glioblastoma) in the brain are presented. �The importance of personalized medicine and clinical validation for targeted therapy are discussed. The identification of various types of biomarkers (determined by molecular genetics) is included, along with their advantages and limitations as markers in tumor detection and diagnosis.
The identification and validation of brain cancer (glioblastoma) genes are discussed. The role of cancer stem cells in the initiation and persistence of malignant gliomas is explained; response of glioblastoma cancer stem cells to various growth factors, such as epidermal growth factor receptor kinase inhibitor, is explained. The use of surgical resection, chemotherapy (e.g., temozolomide), immunotherapy, and radiation therapy for glioblastoma patients is included.
Biological impediments for chemotherapy and radiotherapy for malignant glioblastoma are pointed out. Standard (established) as well as newer imaging modalities (proton magnetic resonance spectroscopy) are discussed. Also included are proton magnetic resonance spectroscopy in intracranial gliomas, and the use of proton magnetic spectroscopic imaging in determining the infiltration zone in gliomas. The role of molecular signaling in the CNS cancer development is explained, including cell death signaling in glioblastoma multiforme.
/ppThe most recent developments in diagnostic and therapeutic aspects of Gliomas (glioblastoma) in the brain are presented. �The importance of personalized medicine and clinical validation for targeted therapy are discussed. The identification of various types of biomarkers (determined by molecular genetics) is included, along with their advantages and limitations as markers in tumor detection and diagnosis.
The identification and validation of brain cancer (glioblastoma) genes are discussed. The role of cancer stem cells in the initiation and persistence of malignant gliomas is explained; response of glioblastoma cancer stem cells to various growth factors, such as epidermal growth factor receptor kinase inhibitor, is explained. The use of surgical resection, chemotherapy (e.g., temozolomide), immunotherapy, and radiation therapy for glioblastoma patients is included.
Biological impediments for chemotherapy and radiotherapy for malignant glioblastoma are pointed out. Standard (established) as well as newer imaging modalities (proton magnetic resonance spectroscopy) are discussed. Also included are proton magnetic resonance spectroscopy in intracranial gliomas, and the use of proton magnetic spectroscopic imaging in determining the infiltration zone in gliomas. The role of molecular signaling in the CNS cancer development is explained, including cell death signaling in glioblastoma multiforme./p
  • Date de parution : 01/10/2011
  • Editeur : Springer
  • ISBN : 9789400720183
  • EAN : 9789400720183
  • Présentation : Cartonné
  • Poids : 0.8 Kg
  • Dimensions : 20,0 cm × 27,3 cm × 2,0 cm

Nos avis clients sur decitre.fr


Avis Trustpilot

Tumors of the Central Nervous System, Volume 5 - Astrocytomas, Hemangioblastomas, and Gangliogliomas est également présent dans les rayons

M. A. Hayat - Tumors of the Central Nervous System, Volume 5 - Astrocytomas, Hemangioblastomas, and Gangliogliomas.
Tumors of the Central Nervous System, Volume...
149,75 €
Haut de page
Decitre utilise des cookies pour vous offrir le meilleur service possible. En continuant votre navigation, vous en acceptez l'utilisation. En savoir plus OK